Paper
26 October 2001 Testing of efficacy of photodynamic therapy with a new photosensitizer: a derivative of chlorin e6 (BLC 1010)
Eugeny Ph. Stranadko, Michail V. Riabov, N. N. Volkova, S. Spaniol, W. Rauschning, N. E. Nifantiev
Author Affiliations +
Abstract
Efficacy of PDT with new chlorin e6 photosensitizer (BLC 1010) has been tested in 72 cancer patients. 44 patients (61 %) achieved a complete response and 39 % of the patients a partial response (28 patients, including 15 patients treated for palliation). Rapid elimination of BLC 1010 from the organism solves the problem of skin phototoxicity encountered in PDT up to now. This property together with its high tumor to normal ratio makes it a promising photosensitizer for PDT. Further advantage is that portable diode lasers with proper wavelength are available.
© (2001) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Eugeny Ph. Stranadko, Michail V. Riabov, N. N. Volkova, S. Spaniol, W. Rauschning, and N. E. Nifantiev "Testing of efficacy of photodynamic therapy with a new photosensitizer: a derivative of chlorin e6 (BLC 1010)", Proc. SPIE 4433, Laser-Tissue Interactions, Therapeutic Applications, and Photodynamic Therapy, (26 October 2001); https://doi.org/10.1117/12.446519
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Photodynamic therapy

Tumors

Cancer

Skin

Skin cancer

Semiconductor lasers

Esophagus

Back to Top